1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.


Methylphenidate is a stimulant drug generally prescribed to treat ADHD and narcolepsy, and has also been used to manage treatment-resistant depression, eating disorders, and as a maintenance drug for those addicted to cocaine or methamphetamine. It is available in both instant-release and a variety of extended-release formulations. Like amphetamine which has a similar molecular structure and comparable potency, the drug works by increasing the amounts of extracellular dopamine and norepinephrine. However, methylphenidate is notable in that it has a half life of just 2-3 hours, much shorter than that of either the dextro or levo isomers of amphetamine whose half lives exceed 10 hours.

Introduction to Methylphenidate


Methylphenidate is a synthetic central nervous system stimulant--also well described as a substituted amphetamine, though its mechanism of action is distinct from the classical amphetamines-- which is prescribed worldwide for a variety of diagnoses, such as Attention-Deficit (Hyperactivity) Disorder, Postural Orthostatic Tachycardia Syndrome, Chronic Fatigue Syndrome, narcolepsy, depression, obesity and (rarely) Obsessive-Compulsive Disorder. It has been shown to possess neuroprotective effects. [1] It is sold as a racemic mixture under the brand names Ritalin, Ritilana, Ritaline, Attenta, Penid, Ribufen, Concerta, Metadate, Methylin and Daytrana.

The compound itself is a member of the piperidine class, and despite not being a member of the same family, it bears some structural resemblance to amphetamine but its effects are likened to those of cocaine.[2]

It is most commonly sold as the water-soluble salt, methylphenidate hydrochloride.


Dexmethylphenidate is the dextrorotatory enantiomer of methylphenidate. It it sold under the brand name Focalin. This differs from the typically racemic form, which is an equal mixture of dextrorotatory and levorotatory molecules.

Use of Methylphenidate

Methylphenidate can provide a very satisfying high, However; when repeatedly abused, the user can build a tolerance to this drug very quickly. A high tolerance will reduce both the recreational and medicinal value of the drug.

Commonly prescribed forms of Methylphenidate


Commonly known as ‘Ritalin’ is the conventional and most commonly prescribed form ofmethylphenidate, It releases the full dose of methylphenidate into the users system almost immediately after consumption.
Ritalin 10mg (Novartis)


Commonly known as ‘Concerta’ releases a small portion of the methylphenidate immediately and gradually releases the rest over a 9 hour period. Concerta is considered more difficult to abuse, It needs to be altered for Instant-release before consumotion, it also somewhat limits the user to oral administration as it is unsuitable for Intranasal or Intravenous use.
Ritalin (Ciba)


Daytrana is a methylphenidate-containing patch which is designed to be placed on the hip so that the drug may be absorbed into the blood through the skin. [4] The slow-release mechanism of transdermal patches intentionally decreases the recreational potential of a drug, but is ideal for treatment.

Routes of Administration for Methylphenidate

Methylphenidate can be taken in a number of ways, some being significantly less dangerous than others.


This is the most common (and arguably safest)- route of administration. Tablets are available in instant release and extended release forms; the latter is designed to give a continuous effect throughout the whole day without the need for re-dosing, however, the recreational value of unaltered Concerta is very minimal.

The oral bioavailability of methylphenidate ranges between 11-52%


Methylphenidate can be insufflated through the nose, where it is absorbed into the bloodstream via mucous membranes. Snorting crushed tablets may cause damage to the inside of the nose via vasoconstriction by the drug itself and corrosion by binders used in pill manufacture. As with cocaine, it is reasonable to assume that long-term abuse in this manner may lead to permanent damage, including destruction of the septum, which separates the nostrils. Thus, it is advised that an extraction be performed to obtain a relatively pure methylphenidate hydrochloride before attempting this, though extraction may reduce, but does not eliminate the potential for damage.

Intravenously injected

This can be very hazardous and is highly unrecommended. It can very easily cause an overdose and can cause potentially permanent peripheral and arterial damage (especially in an un-purified form) as well as carrying other risks such as infections.


The effects and their intensity vary depending on tolerance, dosage, route of administration and how the individual responds to the drug but the effects most commonly consist of:

  • Alertness
    [*]Decreased hyperactivity
    [*]Enhanced libido
    [*]Lengthened attention span
    [*]Mild empathy
    [*]Mood lift
    [*]Physical and mental stimulation


[FONT=Verdana] [h="3"]Side-effects[/h]
Side-effects commonly include:

[*][FONT=Verdana]Abdominal pain
[*][FONT=Verdana][autolink]Addiction[/autolink] (psychological)
[*][FONT=Verdana]Chest pain
[*][FONT=Verdana]Heart palpitations
[*][FONT=Verdana]Loss of appetite
[*][FONT=Verdana]Mydriasis (pupil dilation)

Methylphenidate has [autolink]comedown[/autolink] effects similar to those of [autolink]amphetamines[/autolink] and [autolink]cocaine[/autolink], though usually less severe, The [autolink]comedown[/autolink] effects commonly include

[*][FONT=Verdana] Chill
[*][FONT=Verdana] Craving for more of the [autolink]drug[/autolink]
[*][FONT=Verdana] [autolink]Depression[/autolink]
[*][FONT=Verdana] Dry mouth/Seemingly unquenchable thirst
[*][FONT=Verdana] Excessive sweating
[*][FONT=Verdana] Fever
[*][FONT=Verdana] Headache
[*][FONT=Verdana] Hoarse voice
[*][FONT=Verdana] Insomnia
[*][FONT=Verdana] Irritability
[*][FONT=Verdana] Jaw clenching/Teeth grinding
[*][FONT=Verdana] Muscle pain
[*][FONT=Verdana] Restlessness
[*][FONT=Verdana] Sore throat
[*][FONT=Verdana] Sedation
[*][FONT=Verdana] Shakiness/Tremor
[*][FONT=Verdana] [autolink]Vasoconstriction[/autolink]

Therapeutic|5mg - 20mg
Moderate|15mg - 40mg
Strong|35mg - 60mg

Chronic abuse or very high doses can lead to auditory hallucinations and [autolink]stimulant[/autolink] [wiki]psychosis[/wiki]. [footnote=ref7]Randal G. Ross, M.D. "Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder" [I]American Journal of Psychiatry[/I] 163:1149-1152, July 2006 [URL="https://www.drugs-forum.com/forum/local_links.php?action=ratelink&catid=59&linkid=9237"]https://www.drugs-forum.com/forum/loc...59&linkid=9237[/URL][/footnote] The long-term effects of methylphenidate use are unknown. [footnote=ref8]Kimko HC, Cross JT, Abernethy DR. (1999) "Pharmacokinetics and clinical effectiveness of methylphenidate." [I]Clinical Pharmacokinetics[/I]. 1999 Dec; [B]37[/B] (6): 457-70. [URL]http://www.ncbi.nlm.nih.gov/pubmed/10628897[/URL][/footnote]

[h="3"]Methylphenidate Compared to Amphetamine[/h]
[wiki]Amphetamine[/wiki] is a [autolink]drug[/autolink] with similar effects as methylphenidate; it has the same indications, especially ADD/ADHD. However, methylphenidate is not an [autolink]amphetamine[/autolink], despite structural resemblances. [autolink]Amphetamine[/autolink]'s action slightly differs from methylphenidate's insofar as it also promotes the release of [autolink]neurotransmitters[/autolink] into the synapse and significantly affects [autolink]serotonin[/autolink]. [footnote=ref4]Kuczenski R, Segal DS. "Effects of Methylphenidate on Dopamine, Serotonin and Norepinephrine: A Comparison With Amphetamine (1997)" Journal of Neurochemistry 1997 May; [B]68[/B] (5): 2032-7[/footnote]

A [URL="https://www.drugs-forum.com/forum/poll.php?do=showresults&pollid=54"]Drugs-Forum poll[/URL] shows a significant majority of users preferring the effects of [wiki]Adderall[/wiki] (mixed [autolink]amphetamine[/autolink] salts) over methylphenidate.


Combining methylphenidate with [wiki]alcohol[/wiki] (ethanol) can enhance [autolink]euphoria[/autolink], libido and sociability as well as counteracting [autolink]alcohol[/autolink]'s drowsiness. It also often makes the user feel less drunk than they really are, and can be dangerous for this reason.


[autolink]Ethylphenidate[/autolink] is a homologue of methylphenidate, which has an ethyl - instead of a methyl - group attached to the single-bonded oxygen of the acetate.

[autolink]Ethylphenidate[/autolink] is created in the human body when ethanol and methylphenidate are ingested at the same time, by a process called transesterification. Methanol may be a byproduct of this reaction. The same process results in the formation of [wiki]cocaethylene[/wiki] when [wiki]cocaine[/wiki] and [wiki]alcohol[/wiki] are co-ingested. [footnote=ref9]Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS. "Ethylphenidate Formation In Human Subjects After The Administration of a Single Dose of Methylphenidate and Alcohol" [I]Drug Metabolism and Disposition[/I] 2000 Jun; [B]28[/B] (6): 620-4 [URL="https://www.drugs-forum.com/forum/local_links.php?action=ratelink&catid=59&linkid=4061"]https://www.drugs-forum.com/forum/loc...59&linkid=4061[/URL][/footnote][footnote=ref10]Evgenia V. Pindel, Natalia Y. Kedishvili, et al. "Purification and Cloning of a Broad Substrate Specificity Human Liver Carboxylesterase That Catalyzes the Hydrolysis of Cocaine and Heroin" [I]The Journal of Biological Chemistry[/I] Vol. 272, No. 23, Issue of June 6, pp. 14769–14775, 1997 [URL="https://www.drugs-forum.com/forum/local_links.php?action=ratelink&catid=242&linkid=9457"]https://www.drugs-forum.com/forum/loc...42&linkid=9457[/URL][/footnote]

Methylphenidate is a powerful [autolink]stimulant[/autolink] in its own right but can be combined with others to enhance its efficacy or recreational value. This practice carries overdose dangers as dosage does not directly translate from methylphenidate to other substances, as well as potentially increased risks to the cardiovascular system and of [autolink]psychosis[/autolink].

[wiki]Selective serotonin reuptake inhibitors[/wiki] are prescribed for the treatment of [autolink]depression[/autolink], [autolink]anxiety[/autolink] and Obsessive-Compulsive Disorder. There are no serious dangers inherent to combining methylphenidate with an SSRI. Some [autolink]antidepressants[/autolink], such as [autolink]venlafaxine[/autolink] (Effexor), also inhibit the reuptake of noradrenaline, which can cause feelings of agitation and [wiki]panic attack[/wiki]s when combined with methylphenidate.

[wiki]Monoamine oxidase inhibitors[/wiki] are last resort [wiki]antidepressants[/wiki] which inhibit the action of an enzyme called [autolink][autolink]monoamine[/autolink] oxidase[/autolink] (MAO). MAO's function involves deanimation through the oxidation of [autolink]monoamine[/autolink] compounds (such as [autolink]neurotransmitters[/autolink] [autolink]serotonin[/autolink], [autolink]dopamine[/autolink] and noradrenaline), which renders them inactive. By inhibiting this enzyme, the levels of these [autolink]monoamines[/autolink] increase.

Methylphenidate should [B]never[/B] be taken with an MAOI, and up to two to six weeks or more after taking any MAOI, since the rise in [autolink]dopamine[/autolink], norepinephrine, and [autolink]serotonin[/autolink] levels associated with methylphenidate usage could provoke hypertensive crisis, [autolink][autolink]serotonin[/autolink] syndrome[/autolink], stroke, heart attack and death. The clinical use of combinations of [autolink]stimulants[/autolink], such as methylphenidate, and MAOIs is exclusively done in a hospital setting under very close medical supervision.

[h="1"]Pharmacology of Methylphenidate[/h]

LD[FONT=Verdana][sub]50[/sub] : 190 mg/kg orally in mice (as the hydrochloride salt)

Methylphenidate is a [autolink]dopamine[/autolink] and noradrenaline/norepinephrine reuptake inhibitor (DNRI). It competitively binds to the transporter proteins which remove these [autolink]neurotransmitters[/autolink] from the synaptic cleft, thereby allowing them to agonise receptors for longer. This is similar to the mechanism by which SSRI [autolink]antidepressants[/autolink] inhibit the reuptake of [autolink]serotonin[/autolink]. [footnote=ref3]Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system." [I]CNS Drugs[/I] [B]20[/B] (9): 713–38.[/footnote]
[B][autolink]Dopamine[/autolink][/B] and [B]Noradrenaline[/B]
Endogenous phenethylamine [autolink]neurotransmitters[/autolink].[/FONT][/CENTER][FONT=Verdana]

[FONT=Verdana]It's primary metabolic path is hepatic by the [autolink]cytochrome P450[/autolink] as a substrate inhibitor of enzyme CYP2D6.[footnote=ref11]Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue) 237-43. Epub 2009 Nov 24. http://www.ncbi.nlm.nih.gov/pubmed/19934256[/footnote]
[h="1"]Chemistry of Methylphenidate[/h]

[table]Systematic (IUPAC) name:|[I]α[/I]-Phenyl-2-piperidine-acetic acid methyl ester
Synonyms:|Mehtyl phenidylacetate, methyl α-phenyl-α-(2-piperidyl)acetate, methylphenidan; Ciba 4311b, [autolink]Concerta[/autolink], Equasym, Metadate, [autolink]Ritalin[/autolink] (hydrochloride)
Molecular Formula:|C[sub]14[/sub]H[sub]19[/sub]NO[sub]2[/sub], C[sub]14[/sub]H[sub]19[/sub]NO[sub]2[/sub].HCl (hydrochloride)
Molar mass:| 233.31 g/mol, 269.77 g/mol (hydrochloride) [1]
CAS Registry Number:|113-45-1, 298-59-9 (hydrochloride)
Melting Point:|74-75 °C [3], 224-226°C (hydrochloride)[2][3]
Boiling Point:|135-137°C @ 0.6 mmHg[2]
Flash Point:|no data
Solubility:|Freebase soluble in [autolink]alcohol[/autolink], ethyl acetate, ether[2], acetone[3]; Practically insoluble in water, petroleum ether[2]. Hydrochloride freely soluble in water, methanol[2]; Soluble in [autolink]alcohol[/autolink][2]; Slightly soluble in acetone, chloroform[2].
Additionnal data:|pKa 8.9[2]
Notes:|Hydrochloride aspect : white to off white powder[2]
[H="2"]Reagent test results of [VAR]PAGENAME[/VAR][/H]

[table='head']Reagent | color produced
Liebermann's | Orange[/table][3]


[h="2"]Immediate dangers[/h]
[*][FONT=Verdana]Panic attack

Toxicity [autolink]studies[/autolink] in rats indicate:[footnote=ref12][URL="http://msds.chem.ox.ac.uk/ME/methylphenidate_hydrochloride.html"]http://msds.chem.ox.ac.uk/ME/methylp...ochloride.html[/URL][/footnote]

[TABLE]ROA | Value | Dose
ORL-RAT | [autolink]LD50[/autolink] | 367mg/kg-1
SCU-RAT | [autolink]LD50[/autolink] | 170mg/kg-1
IVN-RAT | [autolink]LD50[/autolink] | 50mg/kg-1
ORL-MUS | [autolink]LD50[/autolink] | 60mg/kg-1
IVN-MUS | LDLO | 40mg/kg-1
ORL-CHD | TDLO | 32mg/kg-1 6w-i
Overdose symptoms include:

[*][FONT=Verdana] [autolink]Anxiety[/autolink]
[*][FONT=Verdana] Chest pain
[*][FONT=Verdana] Feeling faint/Unconsciousness
[*][FONT=Verdana] Hallucinations/Delusions
[*][FONT=Verdana] Irregular or pounding heartbeat/Heart palpitations
[*][FONT=Verdana] Nausea
[*][FONT=Verdana] Paranoia/[URL="https://www.drugs-forum.com/forum/showwiki.php?title=Panic_Attack"]Panic attack[/URL]
[*][FONT=Verdana] Seizures
[*][FONT=Verdana] Tremor/Ticks/Muscle Spasms
[*][FONT=Verdana] Vomiting
[h="2"]Long-term dangers[/h]
[*][FONT=Verdana]Stunted growth
[FONT=Verdana]Investigated as a carcinogen, mutagen and teratogen. No evidence of such activity found. (expand + source)

[h="1"]Producing Methylphenidate[/h]

Methylphenidate was first synthesised 1944 in Basel, Switzerland, by Ciba (Chemische Industrie Basel). [footnote=ref5]Panizzon, L. (1944). "La preparazione di piridil- e piperidil-arilacetonitrili e di alcuni prodotti di trasformazione (Parte Ia)". [I]Helvetica Chimica Acta[/I] [B]27[/B]: 1748–1756. Digital object identifier: [URL="http://dx.doi.org/10.1002%2Fhlca.194402701222"]10.1002/hlca.194402701222[/URL] Last accessed: 22/06/2010[/footnote]

[B]Popularity of Methylphenidate over time:[/B]


[h="1"]Legal Status of Methylphenidate[/h]

[h="2"]United Nations[/h]
Controlled as a schedule 2 [autolink]drug[/autolink] as per the Misuse of [autolink]Drug[/autolink] Regulations, 1988. Possession is only legal on prescription from a licensed medical practitioner, or on permission from the Minister for Health (An tAire Sláinte). Prescriptions cannot be repeated. Illegal possession can result in an unlimited fine and/or a prison sentence of up to seven years. (Misuse of Drugs Act 1984, section 8, subsection 1b)
[h="2"]Central / South America[/h]
[h="2"]North America[/h]

[h="1"]The latest Methylphenidate threads[/h]

[FONT=Verdana][FONT=Verdana][1] Calculated from [I]Atomic Weights of the Elements[/I], 2007
[2] [I]Merck Index[/I], fifteenth edition (2013)
[3] [URL="https://www.drugs-forum.com/forum/local_links.php?action=jump&catid=59&id=14012"]Methylphenidate monograph[/URL][/FONT][/FONT][/FONT][/font][/font][/font][/font][/font][/FONT][/FONT][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/FONT][/FONT][/FONT][/font][/FONT][/FONT][/FONT][/FONT][/font][/FONT][/FONT][/FONT][/FONT][/FONT][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/FONT][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/font][/FONT]

This page has been seen 256,339 times.